Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?

摘要

A woman with heavy pre-treated ovarian cancer sought consultation regarding additional treatments. The case raises the vexing question of whether there may be a time in the course of the disease process where it is most appropriate to state further anti-neoplastic therapy will not be of clinical utility.